Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

ession is responsible for the majority of deaths. The two year loco-regional failure rate following front line treatment is around 30% with a further 20% of patients progressing at a distant site. The long-term loco-regional control rate of 100% combined with the high percentage of patients that remain disease free at up to 40 months from treatment is very encouraging and provides confidence that OncoVEX (GM-CSF) will significantly reduce relapse rates as compared to standard therapy alone in the pivotal study recently agreed with the FDA."

About Head and Neck Cancer

Head and neck cancer accounts for 47,000 new cases (3% of all new cancer cases and 2% of all cancer deaths) in the United States annually; it is the fifth most common malignancy worldwide (an estimated 644,000 new cases annually).

Patients with locally advanced tumors are best treated with concurrent chemoradiation, with planned neck dissection indicated in certain patients. Despite aggressive treatment of locally advanced disease loco-regional recurrences develop in 30% of patients and distant metastases in 20%. Aggressive combined modality therapy may be frequently associated with debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia (dry mouth). As a result, new and improved, and less toxic therapies for head and neck cancer are urgently required.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX (GM-CSF) is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX (GM-CSF) designed to work by; repli
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Md. , Dec. 24, 2014  United ... today that Medtronic, Inc. (NYSE: MDT ... the U.S. Food and Drug Administration (FDA) for ... implantable drug infusion system (including a newly developed ... (treprostinil) Injection delivered intravenously to patients with ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... iKnowMed™, the US Oncology ... vendors selected to participate in the fourth American Society of ... June 5-7 at the 2010 ASCO Annual Meeting ... company uniting the nation,s largest network of community-based oncologists, will ...
... , MENLO PARK, Calif. and KANNAPOLIS, N.C. ... Inc. (ITI) and the David H. Murdock Research Institute (DHMRI) ... Path Research in Immunology (CCPRI) at The David H. Murdock ... Kannapolis, NC . Driven by a mission to accelerate the ...
... , , , ... Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction , ... Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a,developer ... the safety and pharmacodynamics,of five oral insulin formulations in healthy subjects," authored by Dr. ...
Cached Biology Technology:US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 2US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 3US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 4US Oncology(R) to Demonstrate iKnowMed(TM) in the EHR Lab at the 2010 ASCO Annual Meeting 5The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 2The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 3Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 2Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 3
(Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... + Lomb, the global eye health company, announced today that ... unowned shares of Technolas ™ Perfect Vision GmbH (TPV), ... was established in 2009 through a joint venture between Bausch ... sell advanced refractive and cataract technologies. The deal is expected ...
... -- Four innovating life science fields to keep an ... and tissue culture. Thanks to an aging population and ... these markets are on the rise. (Photo: ... (GII) presents four innovative life science market research reports ...
... . , Methane is formed under the absence ... the sea floor. It is a much more powerful greenhouse ... this gas is inactivated before it reaches the atmosphere and ... have now proven that these microorganisms are quite picky about ...
Cached Biology News:Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 2Bausch + Lomb to Acquire Technolas Perfect Vision GmbH 3Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn 2Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn 3Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and Fluorometers to Reach $18.4 bn; Anticoagulants to Reach $12.9 bn; Cell and Tissue Culture Supplies to Reach $5.6 bn 4Strange diet for methane consuming microorganisms 2
Request Info...
... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Validated and Silencer Pre-designed siRNAs, which are ...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: